Prenatal Screening Ontario, Better Outcomes Registry and Network (BORN) Ontario, Ottawa, Canada; Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada.
Prenatal Screening Ontario, Better Outcomes Registry and Network (BORN) Ontario, Ottawa, Canada.
Am J Obstet Gynecol. 2023 Aug;229(2):168.e1-168.e8. doi: 10.1016/j.ajog.2023.01.007. Epub 2023 Jan 7.
Cell-free fetal DNA screening is routinely offered to pregnant individuals to screen for aneuploidies. Although cell-free DNA screening is consistently more accurate than multiple-marker screening, it sometimes fails to yield a result. These test failures and their clinical implications are poorly described in the literature. Some studies suggest that a failed cell-free DNA screening result is associated with increased likelihood of cytogenetic abnormalities.
This study aimed to assess the association between a failed cell-free DNA test and common aneuploidies. The objectives were to determine: (1) the proportion of test failures on first and subsequent attempts, and (2) whether a failed cell-free DNA screen on first attempt is associated with increased likelihood of common aneuploidies (trisomies 21, 18, and 13, and sex chromosome aneuploidies).
This was a population-based retrospective cohort study using data from Ontario's prescribed maternal and child registry, Better Outcomes Registry and Network Ontario. The study included all singleton pregnancies in Ontario with an estimated date of delivery from September 1, 2016 to March 31, 2019 that had a cell-free DNA screening record in the registry. Specific outcomes (trisomies 21, 18, and 13, and sex chromosome aneuploidies) of pregnancies with a failed cell-free DNA screen on first attempt were compared with those of pregnancies with low-risk cell-free DNA-screening results using modified Poisson regression adjusted for funding status (publicly funded vs self-paid), gestational age at screening, method of conception, and maternal age for autosomal aneuploidies.
Our cohort included 35,146 pregnancies that had cell-free DNA screening during the study period. The overall cell-free DNA screening failure rate was 4.8% on first attempt and 2.2% after multiple attempts. An abnormal cytogenetic result for trisomies 21, 18, and 13, or sex chromosome aneuploidies was identified in 19.4% of pregnancies with a failed cell-free DNA screening for which cytogenetic testing was performed. Pregnancies with a failed cell-free DNA screen on first attempt had a relative risk of 130.3 (95% confidence interval, 64.7-262.6) for trisomy 21, trisomy 18, or trisomy 13, and a risk difference of 5.4% (95% confidence interval, 2.6-8.3), compared with pregnancies with a low-risk result. The risk of sex chromosome aneuploidies was not significantly greater in pregnancies with a failed result compared with pregnancies with a low-risk result (relative risk, 2.7; 95% confidence interval, 0.9-7.9; relative difference, 1.2%; 95% confidence interval, -0.9 to 3.2).
Cell-free DNA screening test failures are relatively common. Although repeated testing improves the likelihood of an informative result, pregnancies with a failed cell-free DNA screen upon first attempt remain at increased risk for common autosomal aneuploidies, but not sex chromosome aneuploidies.
游离胎儿 DNA 筛查通常提供给孕妇,以筛查非整倍体。虽然游离 DNA 筛查的准确性始终高于多重标志物筛查,但有时无法得出结果。这些测试失败及其临床意义在文献中描述得很差。一些研究表明,游离 DNA 筛查失败的结果与细胞遗传学异常的可能性增加有关。
本研究旨在评估游离 DNA 检测失败与常见非整倍体之间的关联。目的是确定:(1)首次和后续尝试中检测失败的比例,以及(2)首次尝试时游离 DNA 筛查失败是否与常见非整倍体(三体 21、18 和 13 以及性染色体非整倍体)的可能性增加有关。
这是一项基于人群的回顾性队列研究,使用了安大略省规定的母婴登记处、更好的结果登记处和安大略省网络的数据。研究包括所有在安大略省预计分娩日期为 2016 年 9 月 1 日至 2019 年 3 月 31 日的单胎妊娠,并且在登记处有游离 DNA 筛查记录。使用修正泊松回归,根据资金状况(公共资助与自费)、筛查时的孕龄、受孕方式和母体年龄对性染色体非整倍体进行调整,比较首次尝试游离 DNA 筛查失败的妊娠与低风险游离 DNA 筛查结果的特定结局(三体 21、18 和 13 以及性染色体非整倍体)。
我们的队列包括在研究期间进行游离 DNA 筛查的 35146 例妊娠。首次尝试的游离 DNA 筛查失败率为 4.8%,多次尝试后的失败率为 2.2%。对接受游离 DNA 筛查失败且进行细胞遗传学检测的妊娠,发现三体 21、18 和 13 或性染色体非整倍体的异常细胞遗传学结果的比例为 19.4%。首次尝试游离 DNA 筛查失败的妊娠,21 三体、18 三体或 13 三体的相对风险为 130.3(95%置信区间,64.7-262.6),风险差异为 5.4%(95%置信区间,2.6-8.3),与低风险结果的妊娠相比。与低风险结果的妊娠相比,游离 DNA 筛查失败的妊娠中性染色体非整倍体的风险无显著增加(相对风险,2.7;95%置信区间,0.9-7.9;相对差异,1.2%;95%置信区间,-0.9 至 3.2)。
游离 DNA 筛查测试失败较为常见。尽管重复检测可提高获得有效结果的可能性,但首次尝试游离 DNA 筛查失败的妊娠仍有较高的常见常染色体非整倍体风险,但性染色体非整倍体风险没有增加。